AUTHORS ' CONCLUSIONS Addition of ox and rolone to the GH therapy led to a modest increase in the final adult height of girls aged up to 18 years with TS .
BACKGROUND The final adult height of untreated girls aged up to 18 years with Turner syndrome ( TS ) is approximately 20 cm shorter compared with healthy females .
Treatment with growth hormone ( GH ) increases the adult height of people with TS .
The effects of adding the and rogen , ox and rolone , in addition to GH are unclear .
Therefore , we conducted this systematic review to investigate the benefits and harms of ox and rolone as an adjuvant therapy for people with TS treated with GH .
OBJECTIVES To assess the effects of ox and rolone on growth hormone-treated girls aged up to 18 years with Turner syndrome .
Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome.
CONTEXT AND OBJECTIVE GH therapy increases growth and adult height in Turner syndrome ( TS ) . The benefit to risk ratio of adding the weak and rogen ox and rolone ( Ox ) to GH is unclear . DESIGN AND PARTICIPANTS A r and omized , placebo-controlled , double-blind , dose-response study was performed in 10 centers in The Netherl and s. One hundred thirty-three patients with TS were included in age group 1 ( 2 - 7.99 yr ) , 2 ( 8 - 11.99 yr ) , or 3 ( 12 - 15.99 yr ) . Patients were treated with GH ( 1.33 mg/m(2 ) . d ) from baseline , combined with placebo ( Pl ) or Ox in low ( 0.03 mg/kg . d ) or conventional ( 0.06 mg/kg . d ) dose from the age of 8 yr and estrogens from the age of 12 yr . Adult height gain ( adult height minus predicted adult height ) and safety parameters were systematic ally assessed . RESULTS Compared with GH+Pl , GH+Ox 0.03 increased adult height gain in the intention-to-treat analysis ( mean + /- sd , 9.5 + /- 4.7 vs. 7.2 + /- 4.0 cm , P = 0.02 ) and per- protocol analysis ( 9.8 + /- 4.9 vs. 6.8 + /- 4.4 cm , P = 0.02 ) . Partly due to accelerated bone maturation ( P < 0.001 ) , adult height gain on GH+Ox 0.06 was not significantly different from that on GH+Pl ( 8.3 + /- 4.7 vs. 7.2 + /- 4.0 cm , P = 0.3 ) . Breast development was slower on GH+Ox ( GH+Ox 0.03 , P = 0.02 ; GH+Ox 0.06 , P = 0.05 ) , and more girls reported virilization on GH+Ox 0.06 than on GH+Pl ( P < 0.001 ) . CONCLUSIONS In GH-treated girls with TS , we discourage the use of the conventional Ox dosage ( 0.06 mg/kg . d ) because of its low benefit to risk ratio . The addition of Ox 0.03 mg/kg . d modestly increases adult height gain and has a fairly good safety profile , except for some deceleration of breast development
AUTHORS ' CONCLUSIONS Addition of ox and rolone to the GH therapy led to a modest increase in the final adult height of girls aged up to 18 years with TS .
BACKGROUND The final adult height of untreated girls aged up to 18 years with Turner syndrome ( TS ) is approximately 20 cm shorter compared with healthy females .
Treatment with growth hormone ( GH ) increases the adult height of people with TS .
The effects of adding the and rogen , ox and rolone , in addition to GH are unclear .
Therefore , we conducted this systematic review to investigate the benefits and harms of ox and rolone as an adjuvant therapy for people with TS treated with GH .
OBJECTIVES To assess the effects of ox and rolone on growth hormone-treated girls aged up to 18 years with Turner syndrome .